References
- Ahrengart L, Lindgren U. Functional significance of heterotopic bone formation after total hip arthroplasty. J Arthroplasty 1989; 4: 125–31.
- Ahrengart L, Blomgren G, Törnkvist H. Short-term ibu-profen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 1994; 65: 139–41.
- Brooker A F, Bowerman J W, Robinson R A, Riley L H, Jr. Ectopic ossification following total hip replacement. Inci-dence and a method of classification. J Bone Joint Surg (Am) 1973; 55: 1629–32.
- Brune K. Optimierte Diclofenac-Therapie mit Hilfe gale-nischer Innovationen. In: Jahrbuch der Orthopädie (Eds Venbrocks R, Salis-Soglio G). Biermann-Verlag, Zälpich 1995: 235–41.
- DeLee J, Ferrari A, Chanfley J. Ectopic bone formation fol-lowing low friction arthroplasty of the hip. Clin Orthop 1976; 129: 53–9.
- Fingeroth RJ, Ahmed AQ. Single dose 6 Gy prophylaxis for heterotopic ossification after total hip arthroplasty. Clin Orthop 1995; 397: 131–40.
- Fowler PD, Dawes PT, John VA, Shotton PA. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administra-tion of a 100 mg slow-release formulation. Eur J Clin Pharmacol 1986; 31: 469–72.
- Hanslik L, Radloff H. The pathological significance of paraarticular ossifications after total hip replacements (author's transl). Arch Orthop Unfallchir 1974; 80: 153–64.
- Holz U, Kraner F, Weller S. Periarticular ossification follow-ing replacement of the hip joint. Clinical and radiological examination of 697 hip joints (author's transl). Z Orthop 1977; 115: 146–58.
- Jockheck M, Willms R, Volkmann R, Sell S, Weller S, Kässwetter W. Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac. Arch Orthop Trauma Surg 1998; 117: 337–40.
- Knenes D, Barthel T, Karrer A, Kraus U, Eulert J, Kölbl 0. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg (Br) 1997; 79: 596–602.
- Mäller-FaBbender H. Diclofenac Resinat bei Patienten mit rheumatischen Beschwerden. Eine Anwendungsbeobach-tung an 3839 Patienten. Fortschr Med 1998; 116: 89–94.
- Reis H J, Kiisswetter W, Schellinger T. The suppression of heterotopic ossification after total hip arthroplasty. hit Orthop 1992; 16: 140–5.
- Ritter MA, Vaughan R B. Ectopic ossification after total hip arthroplasty. Predisposing factors, frequency, and effect on results. J Bone Joint Surg (Am) 1977; 59: 345–51.
- Sell S, Schleh T. C-reactive protein as an early indicator of the formation of heterotopic ossifications after total hip replacement. Arch Orthop Trauma Surg 1999; 119: 205–7.
- The SPALA Project Team: The SPALA project—An intensive monitoring system for non-steroidal anti-inflammatory drugs. In: Adverse reactions to non-steroidal anti-inflam-matory drugs (Ed. Kurowski M). Clinical Pharmacoepi-demiology, Birkhäuser Verlag Basel 1992: 51–65.
- Todd PA, Sorkin E M. Diclofenac sodium—a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244–85.
- Wahlström 0, Risto 0, Djerf K, Hammerby S. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. Acta Orthop Scand 1991; 62: 419–21.
- Yeomans N D, Tulassay Z, Juhasz L, Racz I, Howard J M, van Rensburg C J, Swannell A J, Hawkey C J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719–26.